Romero-Maté Alberto, García-Donoso Carmen, Hernández-Núñez Almudena, Martínez-Morán Cristina, Moreno-Torres Amalia, Borbujo-Martínez Jesús
Department of Dermatology, Hospital Universitario de Fuenlabrada, Madrid.
Dermatol Online J. 2017 Jan 15;23(1):13030/qt206538zm.
We report a 52-year old woman with a 28-year historyof disfiguring facial discoid lupus erythematosus(DLE), persistent despite both classical therapiesand rituximab. Ustekinumab 45 mg was started incombination with methotrexate and intralesionalcorticosteroids. Methotrexate and intralesionalcorticosteroids were withdrawn 30 months later andustekinumab maintained as monotherapy. Fortyeight months later stable improvement was achievedwithout side effects. Only nine patients with cutaneouslupus erythematosus (CLE) treated with ustekinumabhave been reported to date. Ustekinumab could be apromising alternative in severe and recalcitrant casesof CLE. Possibly, the Th17-inflammation pathway isplaying a role in these patients.
我们报告了一名52岁女性，患有毁容性面部盘状红斑狼疮（DLE）28年，尽管接受了传统疗法和利妥昔单抗治疗，但病情仍持续存在。开始使用45毫克的优特克单抗联合甲氨蝶呤和皮损内注射皮质类固醇。30个月后停用甲氨蝶呤和皮损内注射皮质类固醇，优特克单抗维持单一疗法。48个月后病情稳定改善且无副作用。迄今为止，仅有9例接受优特克单抗治疗的皮肤红斑狼疮（CLE）患者被报道。对于严重且顽固的CLE病例，优特克单抗可能是一种有前景的替代疗法。可能，Th17炎症途径在这些患者中起作用。
